Adverse events
nausea, pneumonia, leukopenia, toxicity, toxicities, thrombocytopenia, renal toxicity, numbness, hepatic toxicity, anemia, neurotoxicity, insomnia
PNEUMONIA, LEUKOPENIA, THROMBOCYTOPENIA, LIVER DAMAGE, ANEMIA
There were no significant differences in the digestive tract, liver, kidney, heart, or neurotoxicity between the two groups. All patients experienced AEs during treatment, most of which were hematological AEs. The most common hematological toxicities included leukopenia (86%), thrombocytopenia (74%), and anemia (57%). In the decitabine‐RDHAP group, five patients (14%) received at least one red blood cell infusion and 11 patients (31%) received at least one platelet infusion, In the RDHAP group, three patients (14%) received at least one red blood cell infusion and two patients (10%) received at least one platelet infusion. In both groups, non‐hematologic toxicity included pneumonia, nausea, numbness in the extremities, liver damage, and insomnia. These symptoms were effectively relieved with appropriate treatment, and there were no fatal AEs.In the decitabine‐RDHAP group, nine patients had a 20% reduction (cisplatin and cytarabine) due to severe grade 3–4 AEs that did not recover within 2 weeks: six because of a severe decrease in platelet and white blood cell counts; one due to renal toxicity, one due to severe pneumonia, and one due to hepatic toxicity, four of whom delayed the next cycle of chemotherapy.